Phaseline

Companies › Transcenta Therapeutics (Hangzhou)

Transcenta Therapeutics (Hangzhou): clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Gastroenterology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TST001
Anti-CLDN18.2 monoclonal antibody
CLDN18Phase 1Advanced CancerJun 2027
TST003
humanized anti-GREM1 monoclonal antibody
GREM1Phase 1Locally Advanced Solid TumorJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04396821TST001Phase 1Advanced CancerGastroenterologyJun 2027
NCT04495296TST001Phase 1Advanced CancerOncologyJun 2027
NCT05731271TST003Phase 1Locally Advanced Solid TumorOncologyJun 2027

Targets

CLDN18 (1) GREM1 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou) Antengene Biologics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.